Paper - WANFANG MED ONLINE

You Position: Home > Paper

Expert consensus on the treatment of retinopathy of prematurity

( views:443, downloads:47 )

Author:: No author available

Journal Title:: Chinese Journal of Ocular Fundus Diseases

Issue:: 1

DOI:: 10.3760/cma.j.cn511434-20211119-00647

Key Word:: 早产儿视网膜病;治疗规范;多数赞同;Retinopathy of prematurity;Treatment norms;Consensus

Abstract： Retinopathy of prematurity (ROP) is a retinal angioproliferative disease that occurs in premature and low birth weight infants, and is the most common eye disease that causes blindness and low vision in infants. However, there is no systematic standardized guidance on the overall treatment strategy for ROP. Therefore, in order to standardize the treatment of ROP, the Ophthalmology Group of Pediatrics Society of Chinese Medical Association organized relevant domestic experts to put forward standardized opinions on the treatment of ROP in China after repeated discussion, so as to provide clinicians with reference and application in clinical practice.

Reference

[1]李孝纯,曹晓光,黎晓新,等.晚期早产儿视网膜病变巩膜外加压手术及玻璃体切割手术疗效观察[J].2016,(5).
[2]中华医学会眼科学分会眼底病学组.中国早产儿视网膜病变筛查指南（2014年）[J].2014,(12).
[3]程湧,梁建宏,黎晓新.康柏西普玻璃体腔注射治疗急进性后极部早产儿视网膜病变的疗效观察[J].2017,(2).
[4]许宇,朱颖,李家恺,等.4期早产儿视网膜病变玻璃体视网膜手术前玻璃体腔注射抗血管内皮生长因子单克隆抗体bevacizumab的安全性和有效性[J].2012,(1).
[5]中华医学会.早产儿治疗用氧和视网膜病变防治指南[J].2005,(4).
[6]许宇,张琦,季迅达,等.玻璃体腔注射抗血管内皮生长因子单克隆抗体ranibizumab联合激光光凝治疗急进性后部型早产儿视网膜病变的疗效观察[J].2014,(1).
[7]Kennedy KA,Chuang AZ,Mintz Hittner HA.Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.[J].2011,364(7).
[8]Iwahashi-Shima,C.,Miki,A.,Hamasaki,T.,etc.Intraocular pressure elevation is a delayed-onset complication after successful vitrectomy for stages 4 and 5 retinopathy of prematurity[J].2012,32(8).
[9]VanderVeen, Deborah K.,Melia, Michele,Yang, Michael B.,etc.Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity A Report by the American Academy of Ophthalmology[J].2017,124(5).
[10]C-S Yang,A-G Wang,C-S Sung,etc.Long-term visual outcomes of laser-treated threshold retinopathy of prematurity: a study of refractive status at 7 years[J].2009,24(1).
[11]Hellstr?m,A.,Smith,L.E.H.,Dammann,O..Retinopathy of prematurity[J].2013,382(9902).
[12]Cheng, Yong,Zhu, Xuemei,Linghu, Dandan,etc.Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity[J].2020,98(8).
[13]Gerard P,Barry,Yinxi,Yu,Gui-Shuang,Ying,etc.Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.[J].2020.
[14]Çömez Ayşegül,Karaküçük Yalçın,Özmen Mehmet Cüneyt,etc.The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity[J].2021,35(12).
[15]Nudleman, Eric,Muftuoglu, Ilkay Kilic,Gaber, Raouf,etc.Glaucoma after Lens-Sparing Vitrectomy for Advanced Retinopathy of Prematurity[J].2018,125(5).
[16]Martínez-Castellanos Maria A.,González-H.León Ana,Romo-Aguas Juan C.,etc.A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series[J].2020,258(4).
[17]Mintz-Hittner, Helen A.,Geloneck, Megan M.,Chuang, Alice Z..Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy[J].2016,123(9).
[18]Nicoara,S.-D.,Cristian,C.,Irimescu,I.,etc.Diode laser photocoagulation for retinopathy of prematurity: Outcomes after 7 years of treatment[J].2014,51(1).
[19]Toy, Brian C.,Schachar, Ira H.,Tan, Gavin S. W.,etc.Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity[J].2016,123(10).